January 8, 2021 11:13 AM ESTUpdated January 10, 02:40 AM

News briefing: Sanofi ponies up more money to expand protein degradation collab with Nurix; Biogen fires shot at Novartis in new Spinraza trial

Kyle Blankenship

Max Gelman

Senior Editor

Sanofi has agreed to shell out an additional $22 million — bringing its total cash investment to $77 million — to expand a discovery pact with Nurix …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

News briefing: Sanofi ponies up more money to expand protein degradation collab with Nurix; Biogen fires shot at Novartis in new Spinraza trial

Kyle Blankenship

Max Gelman

Senior Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

News brief­ing: Sanofi ponies up more mon­ey to ex­pand pro­tein degra­da­tion col­lab with Nurix; Bio­gen fires shot at No­var­tis in new Spin­raza tri­al

Senior Editor

Sign up to read this article for free.

News briefing: Sanofi ponies up more money to expand protein degradation collab with Nurix; Biogen fires shot at Novartis in new Spinraza trial